SLAM
HRMY icon

Swiss Life Asset Management’s Harmony Biosciences HRMY Stock Holding History

Swiss Life Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,268
Closed -$235K – 1560
2025
Q4 		$235K Buy
+6,268
New +$206K ﹤0.01% 1177

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Swiss Life Asset Management's HRMY Position: Q1 2026 in Review

Swiss Life Asset Management sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 6,268 shares — an estimated $235K sold.

Swiss Life Asset Management first reported a position in HRMY in Q4 2025 and held it in 1 quarter. The position peaked at $235K in Q4 2025. 310 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Swiss Life Asset Management reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Swiss Life Asset Management sold 6,268 Harmony Biosciences shares in Q1 2026, an estimated $235K.
  • Swiss Life Asset Management first reported a position in Harmony Biosciences in Q4 2025 and held it in 1 quarter.
  • Swiss Life Asset Management's Harmony Biosciences position peaked at $235K in Q4 2025.
  • 310 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Swiss Life Asset Management's 13F filing for Q1 2026, filed 14 May 2026.